The Cancer Letter Archives
The Cancer Letter was founded in 1973, two years after Congress passed the National Cancer Act of 1971. These archives represent the first 40 years of The Cancer Letter, which is published weekly.
TCL
Vol.
40
No.
21
May 23, 2014
- MD Anderson Survey Shows Faculty Dissatisfaction with Top Leaders
- In Their Own Words: “Blessed with The Opportunity” vs. “LOWEST Morale Ever”
- Guest Editorial: A Near-Term Solution: NCI And COG Agree on Plan to Maintain Enrollment
- Obituary: Selma Schimmel, Founder of Vital Options, Dies of Cancer
- In Brief: MSKCC Launches Molecular Oncology, Genomic Center
TCL
Vol.
40
No.
22
May 30, 2014
- DePinho Explains Tenure Decision,Professors Dispute Key Details
- DePinho’s Letter to the AAUP
- Boyd’s Rebuttal to DePinho’s Letter to the AAUP
- Moffitt, Ohio State Form Network, Invite Major Cancer Centers to Join
- ASCO 2014: Special Awards
- Funding Opportunity: DOD Offering 10.5 Million For Lung Cancer Research
- In Brief: Big Ten Cancer Research Consortium Names Executive Officer
- Drug Approvals: FDA Approves Vectibix in mCRC With KRAS Companion Diagnostic
CCL
Vol.
37
No.
5
May 30, 2014
- Model Projects 54,900 New Lung Cancer Cases In 5 Years with Nationwide LDCT Screening
- ASCO Publishes Two Clinical Guidelines For Treating HER2-Positive Breast Cancer
- Study: Delaying ADT Until Symptoms Appear Can Be Safe in Men with a PSA-based Relapse
- Two Phase III Afatinib Trials Demonstrate Prolonged Survival
- EGFR Inhibitor Shrinks Tumors In Phase I Study of Patients With Treatment-Resistant Mutation
- VeriStrat Biomarker Test Predicts Treatment Outcomes In Phase III NSCLC Trial
- Researchers Link Obesity With 34% Higher Death Risk In Pre-Menopausal Women
- Targeted Biopsy More Effective At Selecting Men For Active Surveillance, Study Says
- New Biomarker Findings Show Improvement in KRAS Subtype In Phase III Erbitux Trial
- Immunotherapy Shrinks Tumors In Phase I Study at St. Jude
- Anti-Nausea Drug Successful In Phase III Trial in Highly Emetogenic Chemotherapy
- NCI CTEP-Approved Trials For the Month of May
- Orphan Designation Granted To Advaxis HPV Immunotherapy
TCL
Vol.
40
No.
23
June 06, 2014
- A Take-Home Message From ASCO 2014: NCI-Funded Clinical Research In Jeopardy,bSociety Focuses on Value of NCTN Groups
- Hudis’s Address At ASCO 2014: On Value & Commitment
- Semantics: NIH to Drop “Alternative From Center’s Name; Integrative Better Describes Current Focus
- Kansas City Clinic Settles Medicare Overbilling Claim
- An Appreciation: Eddie Reed, 60, a Developer of Taxol
- In Brief: Georgetown, Theurer Form Collaboration; Hopkins To Develop Bladder Cancer Institute
TCL
Vol.
40
No.
24
June 11, 2014
- NCI to Implement More Transparent Formula For Calculating Cancer Center Support Grants
- After the Plenary: Don Berry: In NeoALTTO & ALTTO Trials, Neoadjuvant Response Predicts Adjuvant
- Counter-Point: George Sledge Responds To Berry’s Letter: Neoadjuvant Doesn’t Predict Adjuvant In Breast Cancer
- AACR Changes Its Logo— For The Fifth Time Since 2000
- NIH Funding Opportunity: Outstanding Investigator Award In Cancer Research Available
- In Brief :Three Named to Leadership Posts At St. Jude; Mitchell Weiss Appointed Chair of Hematology
- Drug Development: FDA Grants Breakthrough Therapy Designation To CTL019 in ALL
TCL
Vol.
40
No.
25
June 20, 2014
- Partnership Points to New Path Forward For Drug Approval and Clinical Research
- Conversation With The Cancer Letter: What $34,000 Per Patient Buys In Lung-MAP
- New Cyclotron Delivered To University of Maryland, Instigating D.C.-Area Proton Radiation Competition
- 340B Drug Discount Program: HRSA Defends Orphan Drug Rule
- In Brief : Patricia LoRusso Named Associate Director Of Innovative Medicine at Yale Cancer Center
TCL
Vol.
40
No.
26
June 27, 2014
CCL
Vol.
37
No.
6
June 27, 2014
- Pooled Analysis of Two LUX-Lung Trials Shows Prolonged Survival with Afatinib
- Enzalutamide Reduced Risk of Progression By 81 Percent in Metastatic Prostate Cancer
- Vaccine and LDCT Pretreatment Can Help PDACs Become Vulnerable to Immunotherapy
- Cyramza-Docetaxel Combination Extends OS In Second-Line NSCLC
- Ibrutinib Increases OS, PFS Versus Ofatumumab in Phase III
- Phase III PANORAMA-1 Trial Meets PFS Primary Endpoint
- Phase III Trial Data: Lenvatinib Extends PFS by Over 14 Months
- Vaccine Increases PFS by 4 Months In Phase II Per-Protocol Analysis
- NCI CTEP-Approved Trials For the Month of June
- Lymphoseek Label Updated To Include Head and Neck SCC